Investing.com – Guggenheim initiated coverage on Avalyn Pharma () with a buy rating and an $80 price target. The stock currently trades at $28.84, giving the company a market capitalization of $1.21 billion, suggesting substantial upside potential if the firm’s thesis materializes.
The firm cited high conviction in sales potential for the company’s inhaled antifibrotic treatments for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, which combined affect approximately 300,000 patients. Guggenheim conducted a pulmonary fibrosis survey of 50 physicians and expert interviews highlighting unmet medical needs in the disease areas.
The firm’s thesis centers on AP01, an inhaled pirfenidone currently in a Phase 2 trial called MIST for progressive pulmonary fibrosis with results expected in the second half of 2027. The drug candidate follows positive Phase 1b data and evidence from open-label extension data in pulmonary fibrosis patients.
Guggenheim’s research suggests AP01, AP02, an inhaled nintedanib with Phase 2 results due in the second half of 2027, and AP03, a combination therapy with Phase 1 results expected in the second half of 2027, could become preferred treatments. The firm estimates the U.S. pulmonary fibrosis market has peak sales potential exceeding $30 billion.
Guggenheim projects risk-adjusted 2040 global sales of $3.5 billion in its base case, with approximately $2 billion from AP01 and $1.5 billion from AP02, with 72% of sales coming from the U.S. market.While the company remains unprofitable with a loss of $4.56 per share over the last twelve months, InvestingPro data shows Avalyn maintains a strong financial position with liquid assets exceeding short-term obligations by more than 10 times. The stock has gained 8.3% over the past week, reflecting growing investor interest.
In other recent news, Avalyn Pharma Inc. completed its initial public offering on Nasdaq, raising $345 million in gross proceeds. The company sold 19,166,667 shares of common stock at $18.00 per share, including 2,500,000 additional shares purchased through the underwriters’ overallotment option. Prior to this, Avalyn Pharma had priced its upsized IPO at $18 per share, initially planning to sell 16,666,667 shares to generate $300 million. These financial developments mark a significant milestone for the company as it focuses on inhaled therapies for rare respiratory diseases. Additionally, Avalyn Pharma is set to present updated findings from the ATLAS open-label extension trial at the European Alliance of Associations for Rheumatology conference. The presentation will feature long-term tolerability data for AP01, an inhaled pirfenidone formulation, in patients with progressive pulmonary fibrosis. These recent developments highlight Avalyn Pharma’s progress in both financial and clinical arenas.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.